Anglo-Swedish drug major AstraZeneca’s (LSE: AZN) experimental anifrolumab met the primary and secondary goals of a Phase II study, significantly reducing lupus compared with placebo across multiple endpoints.
The 305 adult participants with seropositive moderate-to-severe systemic lupus erythematosus (SLE) in the trial were randomized to receive one of two doses of intravenous anifrolumab or placebo every four weeks for 48 weeks. The study met its main goal of difference in the percentage of patients achieving response as measured by the SLE Responder Index 4 (SRI4) at day 169, and a sustained reduction of oral corticosteroid use between day 85 and day 169.
The company said that responses occurred for 34.4% of patients receiving the lower dose of anifrolumab and for 28.8% given the higher dose, versus 17.6% for placebo. AstraZeneca stated that the trial met both the established secondary endpoints for efficacy: 51.5% of patients receiving the lower dose of anifrolumab and 38.5% on the higher dose achieved SRI4 response at day 365 with sustained reduction of OCS, compared with 25.5% of those given placebo. The other secondary endpoint of reducing oral corticosteroid use was met.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze